US 12,435,130 B2
Pharmaceutical use of FAM19A5 involved in regulating gliogenesis
Jae Young Seong, Seoul (KR); Jong Ik Hwang, Seoul (KR); Woong Sun, Seoul (KR); Eun Bee Cho, Seoul (KR); and Won-Ki Kim, Seoul (KR)
Assigned to NEURACLE SCIENCE CO., LTD., Seoul (KR)
Filed by Neuracle Science Co., Ltd., Seoul (KR)
Filed on Jul. 11, 2023, as Appl. No. 18/350,287.
Application 18/350,287 is a division of application No. 16/807,902, filed on Mar. 3, 2020, granted, now 11,739,141.
Application 16/807,902 is a division of application No. 15/404,011, filed on Jan. 11, 2017, granted, now 10,640,557, issued on May 5, 2020.
Application 15/404,011 is a division of application No. 14/378,505, granted, now 9,579,398, issued on Feb. 28, 2017, previously published as PCT/KR2013/001179, filed on Feb. 15, 2013.
Claims priority of application No. 10-2012-0015177 (KR), filed on Feb. 15, 2012; and application No. 10-2013-0016094 (KR), filed on Feb. 15, 2013.
Prior Publication US 2024/0166735 A1, May 23, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 48/00 (2006.01); C07K 14/47 (2006.01); C07K 16/18 (2006.01); C12N 15/113 (2010.01); C12Q 1/6886 (2018.01); G01N 33/577 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/24 (2013.01) [A61K 38/1709 (2013.01); A61K 48/00 (2013.01); C07K 14/4701 (2013.01); C07K 14/4702 (2013.01); C07K 16/18 (2013.01); C12N 15/113 (2013.01); C12Q 1/6886 (2013.01); G01N 33/577 (2013.01); G01N 33/6896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/76 (2013.01); C12N 2310/11 (2013.01); C12N 2310/141 (2013.01); C12Q 2600/156 (2013.01); G01N 2333/47 (2013.01)] 15 Claims
 
1. A method of treating a degenerative brain disease, central nervous system disease, and/or central nervous system damage in subject in need thereof, comprising administering to the subject an effective amount of an antibody or a fragment thereof that specifically binds to a family with sequence similarity 19, member A5 (FAM19A5) protein (anti-FAM19A5 antibody), and wherein the degenerative brain disease, central nervous system disease, and/or central nervous system damage is associated with (a) an onset of reactive astrocytes, (b) an increase of the number of oligodendrocyte progenitor cells expressing neuron-glial antigen 2 (NG2) in an early stage of neuronal injury, or (c) both (a) and (b).